Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States

被引:98
|
作者
Ozawa, Sachiko [1 ]
Portnoy, Allison [2 ]
Getaneh, Hiwote [3 ]
Clark, Samantha [4 ]
Knoll, Maria [4 ]
Bishai, David [5 ]
Yang, H. Keri [6 ]
Patwardhan, Pallavi D. [7 ]
机构
[1] Univ North Carolina Chapel Hill, Div Practice Adv & Clin Educ, Eshelman Sch Pharm, Chapel Hill, NC 27514 USA
[2] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA
[3] MDRC, New York, NY USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA
[6] Merck & Co Inc, Ctr Observat & Real World Evidence, West Point, PA USA
[7] Merck & Co Inc, Ctr Observat & Real World Evidence, Lebanon, NH USA
关键词
PNEUMOCOCCAL CONJUGATE VACCINE; COST-EFFECTIVENESS; STATISTICAL LIFE; HEALTH; US; MEASLES; IMPACT; INFLUENZA;
D O I
10.1377/hlthaff.2016.0462
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Vaccines save thousands of lives in the United States every year, but many adults remain unvaccinated. Low rates of vaccine uptake lead to costs to individuals and society in terms of deaths and disabilities, which are avoidable, and they create economic losses from doctor visits, hospitalizations, and lost income. To identify the magnitude of this problem, we calculated the current economic burden that is attributable to vaccine-preventable diseases among US adults. We estimated the total remaining economic burden at approximately $9 billion (plausibility range: $4.7-$ 15.2 billion) in a single year, 2015, from vaccine-preventable diseases related to ten vaccines recommended for adults ages nineteen and older. Unvaccinated individuals are responsible for almost 80 percent, or $7.1 billion, of the financial burden. These results not only indicate the potential economic benefit of increasing adult immunization uptake but also highlight the value of vaccines. Policies should focus on minimizing the negative externalities or spillover effects from the choice not to be vaccinated, while preserving patient autonomy.
引用
收藏
页码:2124 / 2132
页数:9
相关论文
共 50 条
  • [31] Vaccine Refusal and the Risks of Vaccine-Preventable Diseases
    Leask, Julie
    McIntyre, Peter B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (07): : 723 - 723
  • [32] Postexposure Management of Vaccine-Preventable Diseases
    Woo, Teri Moser
    JOURNAL OF PEDIATRIC HEALTH CARE, 2016, 30 (02) : 173 - 182
  • [33] Vaccine-preventable diseases in health care
    Kessler, ER
    OCCUPATIONAL MEDICINE-STATE OF THE ART REVIEWS, 1997, 12 (04): : 731 - 739
  • [34] Vaccine-Preventable Diseases Requiring Hospitalization
    Williamson, Gregory
    Ahmed, Bilaal
    Kumar, Parvathi S.
    Ostrov, Barbara E.
    Ericson, Jessica E.
    PEDIATRICS, 2017, 140 (03)
  • [35] Vaccination and vaccine-preventable diseases in Africa
    Sinumvayo, Jean Paul
    Munezero, Pierre Celestin
    Tope, Adegboyega Taofeek
    Adeyemo, Rasheed Omotayo
    Bale, Muritala Issa
    Mutsaka-Makuvaza, Masceline Jenipher
    Daba, Tolessa Muleta
    Nyandwi, Jean Baptiste
    Nzungize, Lambert
    Mutumwinka, Diane
    Omotayo, Moshood O.
    Bello, Muhammad Bashir
    Adedeji, Kudirat Aderonke
    Mutesa, Leon
    Adedeji, Ahmed Adebowale
    SCIENTIFIC AFRICAN, 2024, 24
  • [36] Vaccine-preventable childhood diseases in Australia
    Frost, GW
    Johns, M
    MEDICAL JOURNAL OF AUSTRALIA, 1996, 164 (02) : 61 - 62
  • [37] The Vicar of Vicarious Vaccine-Preventable Diseases
    Block, Stan L.
    PEDIATRIC ANNALS, 2014, 43 (06): : 214 - 219
  • [38] Immune surveillance for vaccine-preventable diseases
    den Hartog, Gerco
    van Binnendijk, Rob
    Buisman, Anne-Marie
    Berbers, Guy A. M.
    van der Klis, Fiona R. M.
    EXPERT REVIEW OF VACCINES, 2020, 19 (04) : 327 - 339
  • [39] Vaccine-preventable diseases and war in Ukraine
    Armitage, R. C.
    PUBLIC HEALTH, 2022, 209 : E7 - E8
  • [40] Vaccine-Preventable Diseases in Older Adults
    Al-Jabri, Maha
    Rosero, Christian
    Saade, Elie A.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2023, 37 (01) : 103 - 121